| Number of studies | Number of patients in GDT group | Patients with complications in GDT group (%) | Number of patients in control group | Patients with complications in control group (%) | Odds ratio | 95% CI | P-value |
---|---|---|---|---|---|---|---|---|
Risk group | Â | Â | Â | Â | Â | Â | Â | Â |
   Intermediate risk | 13 | 727 | 194(26.7) | 698 | 288 (41.3) | 0.43 | 0.27-0.67 | 0.0002 |
   High risk | 10 | 449 | 149 (33.2) | 395 | 184 (46.6) | 0.56 | 0.36-0.89 | 0.01 |
   Extremely high risk | 4 | 89 | 25 (28.1) | 119 | 67 (56.3) | 0.27 | 0.15-0.51 | <0.0001 |
Fluid/inotropes | Â | Â | Â | Â | Â | Â | Â | Â |
   Fluid | 12 | 610 | 198 (32.5) | 636 | 299 (47.0) | 0.47 | 0.30-0.73 | 0.0007 |
   Fluid + inotrope | 15 | 653 | 170 (26.0) | 578 | 240 (41.5) | 0.44 | 0.30-0.64 | <0.0001 |
Goal | Â | Â | Â | Â | Â | Â | Â | Â |
   Supranormal | 8 | 312 | 101 (32.4) | 297 | 153 (51.5) | 0.34 | 0.23-0.51 | <0.00001 |
   Normal | 19 | 951 | 267 (28.1) | 917 | 386 (42.1) | 0.51 | 0.36-0.73 | 0.0002 |
Target | Â | Â | Â | Â | Â | Â | Â | Â |
   CI/DO2I | 14 | 621 | 162 (26.1) | 538 | 229 (42.6) | 0.41 | 0.28-0.61 | <0.0001 |
   FTc/SV | 7 | 361 | 118 (32.7) | 392 | 180 (45.9) | 0.50 | 0.30-0.84 | 0.009 |
   Other | 6 | 281 | 88 (31.3) | 284 | 130 (45.8) | 0.48 | 0.22-1.04 | 0.06 |
Type of monitor | Â | Â | Â | Â | Â | Â | Â | Â |
   PAC | 10 | 441 | 99 (22.4) | 391 | 129 (33.0) | 0.49 | 0.30-0.80 | 0.005 |
   ODM | 6 | 316 | 92 (29.1) | 347 | 150 (43.2) | 0.46 | 0.25-0.86 | 0.01 |
   Other | 1! | 506 | 177 (35.0) | 476 | 260 (54.6) | 0.41 | 0.26-0.64 | 0.0001 |